Adriano Venditti, MD, is an Associate Professor in the Department of Hematology, at the Tor Vergata University of Rome, Rome, Italy. He is a member of the Board of the Italian Society of Hematology, and is also a member of the GIMEMA Acute Leukemia Working Party and the EORTC Acute Leukemia Working Party.
Dr Venditti received his medical degree from the University of Rome, after which he completed fellowships at the Royal Free Hospital, London, UK, and the Royal Marsden Hospital, London, UK. During this time he was Assistant Member at the Department of Hematology at the Tor Vergata University of Rome.
Currently, Dr Venditti is a member of the American Society of Hematology, American Society of Clinical Oncology, and the European Hematology Association. Dr Venditti has authored or co-authored more than 200 published papers.
Speaking on flow cytometry characterisation of malignant hemopathies
Dr Venditti specialises in the field of oncology, with particular focus on acute and chronic leukemia, myelodysplastic syndromes, and malignant hemopathies. He has participated in several clinical trials, which have included the use of retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia, a study looking into the amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio and how this can predict outcomes in acute myeloid leukemia, and the clinical significance of CD38 expression in chronic lymphocytic leukemia.